Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
Renal complications occur in more than half of patients with beta thalassemia, but research on their epidemiology and treatment is limited.
Despite the increasing availability of gene sequencing, several barriers prevent it from having utility as a tool for diagnosis of type 1 von Willebrand disease.
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Due to conflicting literature, there is currently no consensus on the appropriate standard of care for managing polycythemia vera.
Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Second-line treatment strategies for severe aplastic anemia include stem cell transplant, immunosuppressive therapy, and thrombopoietin mimetics.
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Lack of resources and poor awareness of thalassemia can make it difficult for patients with beta thalassemia to receive necessary blood transfusions.
Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Researchers highlighted the current status of diagnostic strategies and laboratory screening tests for von Willebrand disease.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
Group O Rh(D)-negative blood cells can be administered to patients with any ABO Rh(D) type, making them a valuable but limited resource.
In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Treatment strategies for children with hemophilia who have inhibitors should involve eradicating the inhibitor and managing bleeding.
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
Currently, molecular testing occurs at the tail end of the diagnostic workflow for inherited bleeding disorders.
Variation in disease phenotype and clinical circumstances makes it difficult to create a standardized treatment approach to von Willebrand disease.
Patients with atrial fibrillation and cancer may be at higher risk for thromboembolic events.
Identifying patients with smoldering myeloma at high risk for disease progression may allow for implementation of better treatment strategies.
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.